Assessment

• Assess for change in severity of HIV symptoms and for symptoms of opportunistic infections during therapy

• Assess patient for rash (mild to moderate rash usually occurs in the 2nd wk of therapy and resolves within 1–2 wks of continued therapy. If rash is severe (extensive erythematous or maculopapular rash with moist desquamation or angioedema) or accompanied by systemic symptoms (serum sickness-like reaction, Stevens—Johnson syndrome, toxic epidermal necrolysis), therapy must be discontinued immediately.

• Monitor viral load and CD4 cell count regularly during therapy

» Monitor liver function tests periodically during therapy. May cause serum AST, ALT concentrations

» May cause pancreatic amylase and lipase

» May cause in total cholesterol, low density lipoprotein, serum triglyceride, and glucose levels

» May cause serum creatinine

» May cause neutrophils, platelet count, anemia and hemolytic anemia

etravirine is a sample topic found in Davis's Drug Guide. All other sections of this record are viewable by clicking on the index in the left column, or by clicking on "Display all Sections" in the "Content Manager".

To find other Davis's Drug Guide topics, please login or purchase a subscription.